d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder.
Eur Psychiatry
; 40: 38-44, 2017 02.
Article
em En
| MEDLINE
| ID: mdl-27837671
ABSTRACT
BACKGROUND:
Preliminary studies have shown that the addition of the partial NMDA-agonist d-cycloserine (DCS) might be promising in enhancing the results of exposure therapy in obsessive-compulsive disorder (OCD). We examined the effect of DCS addition to exposure therapy in a somewhat larger sample of OCD patients with special attention to subgroups, because of the heterogeneity of OCD.METHODS:
A randomized, double-blind, placebo controlled trial was conducted in 39 patients with OCD. Patients received 6 guided exposure sessions, once a week. One hour before each session 125mg DCS or placebo was administered.RESULTS:
Scores on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) declined more in the DCS group than in the placebo group, but the difference did not reach statistical significance (P=0.076, partial η2=0.13). Response percentages also did not differ between the DCS and the placebo group (37% and 15% respectively). In the 'cleaning/contamination' subgroup a significant effect was found in favour of DCS (P=0.033, partial η2=0.297).CONCLUSIONS:
The results of this study did not support the application of DCS to exposure therapy in OCD. Some specific aspects need further investigation efficacy of DCS in a larger 'cleaning/contamination' (sub-)group, DCS addition only after successful sessions, interaction with antidepressants.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Cognitivo-Comportamental
/
Ciclosserina
/
Antidepressivos
/
Transtorno Obsessivo-Compulsivo
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur Psychiatry
Assunto da revista:
PSIQUIATRIA
Ano de publicação:
2017
Tipo de documento:
Article